早期脉冲染料激光治疗烧伤增生性瘢痕的随机对照试验
ELABS试验在英国七中心纳入153例烧伤愈合三个月内的患者,1:1随机接受标准护理加三次脉冲染料激光或单纯标准护理,最终138例完成分析。六个月时早期激光组患者自评瘢痕质量(POSAS)有统计学显著改善(p=0.041),患者感知变化亦有改善(p=0.01),但生活质量、观察者评分及颜色测量无显著差异,且六个月时未达成本效果阈值。
要点
- 早期脉冲染料激光可改善患者自评瘢痕质量(p=0.041)及感知变化(p=0.01)。
- 生活质量、观察者评分及颜色测量未见统计学显著差异。
- 六个月时未达每QALY两万英镑支付意愿阈值的成本效果。
核心结论
- 早期脉冲染料激光治疗增生性烧伤瘢痕安全,六个月时改善患者自评瘢痕质量但未改善生活质量。
- 因瘢痕成熟过程漫长且动态,需两年以上长期随访以明确最终临床效果并作出成本效果定论。
研究设计与样本
- 英国七中心平行组随机对照试验,评估脉冲染料激光的有效性与成本效果。
- 纳入标准为烧伤创面愈合三个月内,排除有瘢痕疙瘩史或年龄小于16岁者。
- 2021年11月17日至2023年6月30日共招募153例(男77例,女76例),按中心分层1:1随机。
- 最终完整病例分析纳入138例(每组69例),两组均接受标准护理,干预组另接受三次脉冲染料激光治疗。
- 主要结局为六个月时患者自评瘢痕质量(POSAS),试验注册号ISRCTN14392301。
主要发现
- 六个月时早期脉冲染料激光组患者自评瘢痕质量较标准护理组有统计学显著改善(p=0.041)。
- 次要结局患者感知瘢痕质量变化亦有统计学显著改善(p=0.01)。
- 生活质量、观察者评分POSAS瘢痕质量及颜色测量均无统计学显著差异。
- 六个月随访时,在每QALY两万英镑支付意愿阈值下早期脉冲染料激光不具成本效果。
- 未发生与干预相关的非预期不良事件。
临床怎么用
- 原文结论认为早期脉冲染料激光治疗增生性烧伤瘢痕安全,六个月时改善患者自评瘢痕质量但未改善生活质量。
- 原文指出因瘢痕成熟漫长且动态,需两年以上长期随访以理解对瘢痕结局的最终临床效果并作出成本效果定论。
局限性
- 原文指出因瘢痕成熟过程漫长且动态,需两年以上长期随访以理解最终临床效果并作出成本效果定论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypertrophic burn scarring (HBS) is described as "the greatest unmet challenge after burn injury". This ELABS trial hypothesised that early pulsed dye laser (PDL) treatment of HBS improves both scar quality and quality of life (QoL). METHODS: A parallel arm randomised controlled trial to assess the effectiveness and cost-effectiveness of PDL was undertaken at seven centres in the UK. Patients were eligible if their burn injury was within three months of wound healing, and ineligible either with history of keloid scarring or aged < 16 years. A total of 153 (77 male, 76 female) participants were recruited between Nov 17, 2021, and Jun 30, 2023, and were randomised using software in a 1:1 ratio stratified by study centre; 138 (69 each arm) were included in the final complete-case analysis. Both study arms received standard care, and the intervention arm received three PDL treatments. The primary outcome was patient-rated scar quality (POSAS) at six months. The trial was registered with International Standard Randomised Controlled Trial Number registry (ISRCTN14392301). FINDINGS: Early PDL showed a statistically significant improvement in patient-rated scar quality (p = 0·041) and the secondary outcome, participant's perception of change in scar quality (p = 0·01), at six months. There were no statistically significant differences for Quality-of-Life, observer-rated POSAS scar quality, or colour measurement. Early PDL was not cost-effective at 6 months follow-up for the willingness-to-pay threshold of £20,000 per Quality-Adjusted-Life-Year (QALY). There were no unexpected adverse events related to the intervention. INTERPRETATION: Early PDL treatment of HBS is safe and shows improvement for patient-rated scar quality but not QoL at six months. As scar maturation is prolonged and dynamic, longer-term follow-up of upwards of two years is required both to understand the eventual clinical effect on scar outcome and to make any definitive conclusion concerning cost-effectiveness.
引用
- Brewin MP, Docherty S, Heaslip V, et al. Early Laser for Burn Scars (ELABS) - Randomised controlled trial of pulsed dye laser treatment and standard care versus standard care alone for the treatment of hypertrophic burn scars. Burns. 2025. PMID: 40319828. doi:10.1016/j.burns.2025.107500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。